Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update

Enlivex Therapeutics Ltd. (NASDAQ:ENLVGet Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 261,500 shares, a growth of 15.4% from the February 29th total of 226,600 shares. Based on an average daily trading volume, of 108,300 shares, the short-interest ratio is presently 2.4 days.

Institutional Investors Weigh In On Enlivex Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ENLV. Jane Street Group LLC lifted its stake in Enlivex Therapeutics by 89.6% during the first quarter. Jane Street Group LLC now owns 52,507 shares of the company’s stock worth $294,000 after purchasing an additional 24,807 shares in the last quarter. UBS Group AG lifted its stake in Enlivex Therapeutics by 73.4% during the 3rd quarter. UBS Group AG now owns 31,871 shares of the company’s stock worth $136,000 after acquiring an additional 13,490 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in Enlivex Therapeutics during the 1st quarter worth about $68,000. Finally, Bank of America Corp DE boosted its holdings in Enlivex Therapeutics by 87.0% during the 1st quarter. Bank of America Corp DE now owns 6,163 shares of the company’s stock valued at $34,000 after acquiring an additional 2,867 shares during the period. Hedge funds and other institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Stock Up 1.0 %

Shares of ENLV traded up $0.04 during midday trading on Tuesday, reaching $4.04. The company had a trading volume of 142,863 shares, compared to its average volume of 95,552. Enlivex Therapeutics has a 1-year low of $1.20 and a 1-year high of $4.37. The firm has a 50 day simple moving average of $3.35 and a 200-day simple moving average of $2.45. The stock has a market cap of $75.02 million, a PE ratio of -2.75 and a beta of 1.02.

About Enlivex Therapeutics

(Get Free Report)

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.

Featured Articles

Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.